论文部分内容阅读
本文报道了EP—CMC方案交替使用治疗初治的小细胞癌37例,其中局限型15例,广泛型22例。局限型CR率40％,PR53％,CR+PR93％;广泛型中CR23％,PR45％,CR+PR68％,总的有效率为78％。37例中24例随访一年以上,一年生存率及中位生存期局限型与广泛型依次分别为40％,36％,及11个月,6个月。 毒性反应大部分WHO分级Ⅰ—Ⅱ级,主要为恶心和呕吐,白细胞下降,未出现肾毒和听力减退。 以上资料提示,使用二种无交叉耐药的方案治疗小细胞肺癌,近期疗效较为满意。但远期疗效尚不理想,毒副反应均能接受。因此如何提高小细胞肺癌病人的远期疗效,有待进一步探讨。
This article reported the use of the EP-CMC regimen in the treatment of 37 newly diagnosed small cell carcinomas, of which 15 were localized and 22 were extensive. The limited CR rate was 40%, PR53%, and CR+PR93%. In the broad type, CR23%, PR45%, CR+PR68%, and the total effective rate was 78%. Of the 37 cases, 24 were followed up for more than one year. The one-year survival rate and median survival time were 40%, 36%, and 11 months and 6 months, respectively. Toxicity Most WHO grades I-II, mainly nausea and vomiting, leukopenia, no nephrotoxicity and hearing loss. The above data suggest that the use of two non-cross-resistance programs for the treatment of small cell lung cancer, the recent curative effect is more satisfactory. However, long-term efficacy is still not ideal, and toxic and side effects can be accepted. Therefore, how to improve the long-term efficacy of patients with small cell lung cancer remains to be further explored.